Teva meets main goal in trial for its migraine prevention in children and adolescents
by
Contributor since / Followers
Contributor since / Followers
4 months ago
- Teva Pharmaceutical (NYSE:TEVA) announced positive topline results from its late-stage study evaluating the efficacy of AJOVY (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17 years.
- The trial met its primary end point with AJOVY (fremanezumab) achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo.
- Safety data was consistent with that observed in adult populations, with no emergent safety signals. Full data from the SPACE study will be presented at a medical meeting later this year.
- Source: Press Release